McMahon Gerald PhD

SEC source: 0001209191-21-006302 · doc4.xml · derivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,470

Underlying: Common Stock · 181,470 shares

Expires 2031-01-27

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 1/48th of the shares subject to the option on February 28, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments at the end of each month, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

SEC source: 0001209191-20-006700 · doc4.xml · derivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,210

Underlying: Common Stock · 165,210 shares

Expires 2030-01-30

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 1/48th of the shares subject to the option on February 29, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments at the end of each month, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

SEC source: 0001209191-19-048821 · doc4.xml · derivative · entry 2

McMahon Gerald PhD · CIK 0001290747 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 318,590

Underlying: Common Stock · 169,462 shares

Expires 2027-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on December 19, 2017, and thereafter vested as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

SEC source: 0001209191-19-048821 · doc4.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,462

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-030200 · doc4.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

SEC source: 0001209191-19-028675 · doc4.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

SEC source: 0001209191-19-027964 · doc4.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

F1 · price: Represents the weighted average purchase price per share. The shares were purchased at prices ranging from $10.510 to $10.546 per share. Full information regarding the number of shares purchased at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001179110-18-013378 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,697

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment severance agreement the ("Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings ("Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on December 3, 2018, the Issuer issued 5,343 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,824 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of its Common Stock to the Reporting Person.

SEC source: 0001179110-18-012450 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 183,521

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock. par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on November 1, 2018, the Issuer issued 5,466 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,888 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-18-011797 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 186,409

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment severance agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on October 1, 2018, the Issuer issued 5,466 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,888 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001182489-18-000319 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,297

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment severance agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, On September 4, 2018, the Issuer issued 5,541 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,813 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-18-010087 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,110

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on August 1, 2018, the Issuer issued 5,541 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,813 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-18-009240 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,923

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on July 2, 2018, the Issuer issued 5,541 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,813 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-18-008560 · edgar.xml · derivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,000

Underlying: Common Stock · 67,000 shares

Expires 2028-06-13

F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

SEC source: 0001179110-18-007858 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,736

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on June 1, 2018, the Issuer issued 5,541 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,813 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-18-006035 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,549

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on May 1, 2018, the Issuer issued 5,541 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,813 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-18-005108 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 203,362

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on April 2, 2018, the Issuer issued 4,975 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,379 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-18-003192 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,741

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on March 1, 2018, the Issuer issued 4,939 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,415 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-18-001407 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,156

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on February 1, 2018, the Issuer issued 4,939 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,415 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-18-000173 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,571

F1 · balance_after: On November 28,2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person on equal monthly installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, On January 2, 2018, the Issuer issued 4,689 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,665 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-17-014753 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,236

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on December 1, 2017, the Issuer issued 5,142 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,212 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-17-013647 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 220,448

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on November 1, 2017, the Issuer issued 5,142 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,212 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-17-012836 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 223,660

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement")with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15,2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on October 2, 2017, the Issuer issued 5,142 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,212 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-17-011972 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 226,872

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings"). The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on September 1, 2017, the Issuer issued 5,142 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,212 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-17-010880 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,084

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings"). The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on August 1, 2017, the Issuer issued 5,485 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,869 shares of is Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-17-009994 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,953

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings"). The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on July 3, 2017, the Issuer issued 5,485 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,869 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-17-009167 · edgar.xml · derivative · entry 2

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-06-15

F2 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F3 · derivative.exercise_date: Such option vests in three equal annual installments beginning June 15, 2018.

SEC source: 0001179110-17-009167 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 235,822

F1 · price: On June 15, 2017, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions.

SEC source: 0001179110-17-008265 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,822

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings"). The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on June 1, 2017, the Issuer issued 5,485 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,869 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-17-006306 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,691

F1 · balance_after: On November 28,2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings"). The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on May 1, 2017, the Issuer issued 5,485 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,869 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-17-005387 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 231,560

F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings"). The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. 66,839 shares of Common Stock, less Withholdings were issued to Reporting Person in March 2017 and the remaining 200,517 shares of Common Stock, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018.

F2 · balance_after: Pursuant to the Severance Agreement, on April 3, 2017, the Issuer issued 5,485 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,869 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-17-003751 · edgar.xml · nonDerivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 234,429

F1 · balance_after: On November 28, 2016, in connection with Reporting Person's employment separation with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings"). 200,517 shares of Common Stock, less Withholdings, will be issued to Reporting Person ratably over 24 months commencing in the first quarter of 2017 and 66,839 shares of Common Stock, less Withholdings will be issued not later than March 15, 2017. The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016.

F2 · balance_after: Pursuant to the Severance Agreement, on March 1, 2017, the Issuer issued 59,182 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 32,927 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

SEC source: 0001179110-16-033000 · edgar.xml · derivative · entry 1

McMahon Gerald PhD · CIK 0001290747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2026-12-14

F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F2 · derivative.exercise_date: 100% of the total amount of shares subject to the Option vests on December 14, 2017.